Eribulin mesylate for the treatment of late-stage breast cancer
- 17 November 2011
- journal article
- editorial
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 12 (18) , 2883-2890
Abstract
(2011). Eribulin mesylate for the treatment of late-stage breast cancer. Expert Opinion on Pharmacotherapy: Vol. 12, No. 18, pp. 2883-2890. doi: 10.1517/14656566.2011.637490Keywords
This publication has 21 references indexed in Scilit:
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing ConditionsCancer Research, 2011
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic InstabilityBiochemistry, 2009
- Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2009
- Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline TreatmentJournal of Clinical Oncology, 2008
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMolecular Cancer Therapeutics, 2008
- The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMolecular Cancer Therapeutics, 2005
- Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389Cancer Research, 2004
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Total synthesis of halichondrin B and norhalichondrin BJournal of the American Chemical Society, 1992